Chiron Corporation

University of Alberta

Novartis Vaccines & Diagnostics, Gmbh

W. L. Gore & Associates, Inc.

G.d. Searle & Company

Medizinische Hochschule Hannover

Novartis Ag

Arrowhead Research Corporation

The Director General of the National Institute of Health of Japan

Helmholtz Center for Infection Research

Cordis Corporation

Gore Enterprise Holdings, Inc.

Glaxosmithkline Biologicals Sa

Michael Houghton

Qui-Lim Choo

George Kuo

Amy J Weiner

Mark J Selby

Jang Hyun Han

Abdolamir Landi

John L Law

Darren Hockman

Michael Logan

Angelica Medina-Selby

Doris Guenzi Coit

D Lorne Tyrrell

Kent B Thudium

John Andrew Hall

Frank I Marcus

Michael Vajdy

Kenneth R Newcomb

Robert O Ralston

Kim M Berger

Chao Chen

Kang-Sheng Wang

Amy Joan Weiner

Lacy Rasco Overby

Barbara A Gervase

Janice A Kolberg

Bruce D Irvine

David Y Chien

Alex R Hobson

Richard R Spaete

David R King

Joseph E Korleski, Jr

Peter J Roeber

Sergio Abrignani

Leslie D Bell

John C Smith

Paul G Boseley

John Streeter

Michael S Urdea

Tatsuo Miyamura

Jeffrey C Towler

James Nieman

Tai-An Cha

Kathelyn S Steimer

Derek T O'Hagan

David Christopher Majercak

Sherif A Eskaros

John J Donnelly

Colin McCoin

Edward Glazer

Joonho Choe

Michael Manns

Carlos A Guzman

Thomas Ebensen

Byoung J Yoo

Byung S Suh

Brian C Lentz

Tim Lankisch

Tobias Weismueller

Xavier Paliard

D Lorne J Tyrrell

Izumi Saito

Alfred A Alpini

Mostofa Hena

Jack Jhamandas

Wen Fu

Appan Srinivas Kandadai

Alexandr Belovodskiy

Rakesh Kumar Bhat

Ryoichi Kimura

Kamlesh Kumar Sahu

Yin-Ling Lin

Sakthi Sambandam

Michael A Joyce

Clifford P Warner

Sergio Pichuantes

Charles A Harrington

Taewoo Kwon

Yiu-Lian Fong

Mi-Young Seo

Adrian Egli

Deanna Michelle Santer

Jens Martin Heile

Aviad Yaagov Levin

Bradley Scott Thomas

Khaled Hassan Sayed Barakat

Daire Thomas O'Shea

Maurizia Rossana Brunetto

Ferrucio Bonino

Aldo Montano-Loza

Ana Clementin

Atul Humar

Deepali Kumar

Oui-Lim Choo

David Broadhurst

Bing Bai

Hyun Chul Song

Yifei Zhu

William Andrews

Stephen Coates

The present disclosure provides compounds that are amylin receptor antagonist compounds, compositions that include the subject compounds, methods for preparing and using the amylin receptor antagonists, and compositions containing the amylin receptor antagonists for treating, preventing, or ameliorating Alzheimer's disease. Aspects of the present disclosure include a method of inhibiting activity of an amylin receptor by administering to a subject in need thereof a therapeutically effective amount of an amylin receptor antagonist.

Compounds for the treatment of Alzheimer's disease

The present disclosure provides an immunogenic composition comprising: a) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; b) a T-cell epitope polypeptide comprising a T-cell epitope present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide. The present disclosure provides an immunogenic composition comprising: a) a polypeptide that comprises one or more T-cell epitopes present in an HCV protein other than E1 and E2; and b) a pharmaceutically acceptable excipient.

Hepatitis C virus immunogenic compositions and methods of use thereof

The present disclosure provides affinity tagged heterodimeric polypeptides comprising a hepatitis C virus (HCV) E1 polypeptide and an HCV E2 polypeptide, where one or both of the E1 and E2 polypeptides comprises an affinity tag. The present disclosure provides a method of producing an affinity tagged E1/E2 heterodimer of the present disclosure. The present disclosure provides methods of producing untagged HCV E1/E2 heterodimers. The present disclosure provides HCV E1/E2 heterodimers, compositions comprising same, and methods of inducing an immune response to HCV.

Hepatitis c virus E1/E2 heterodimers and methods of producing same

The present disclosure provides an immunogenic composition comprising: a) i) a hepatitis C virus (HCV) heterodimeric polypeptide that includes HCV E1 and E2 polypeptides; ii) an HCV E1 polypeptide; or iii) an HCV E2 polypeptide; b) a polypeptide (also referred to herein as a 'T-cell epitope polypeptide' or an “HCV T-cell epitope polypeptide”) comprising T-cell epitopes (e.g., CD4and CD8T-cell epitopes that are conserved among some HCV genotypes and that are presented through one or multiple HLA alleles common within the human population) present in an HCV protein other than E1 and E2; and c) a pharmaceutically acceptable excipient. The present disclosure provides a method of inducing an immune response, in an individual, to an HCV polypeptide.

Hepatitis C virus peptide compositions and methods of use thereof

The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

The present disclosure provides heterodimeric polypeptides comprising: 1) a variant hepatitis C virus (HCV) E2 polypeptide and an HCV E1 polypeptide; 2) a variant HCV E1 polypeptide and an HCV E2 polypeptide; or 3) a variant HCV E1 polypeptide and a variant HCV E2 polypeptide, where the variant HCV E2 polypeptide and/or the HCV E1 polypeptide comprises one or more T cell epitopes, present in an HCV polypeptide other than an HCV E1 polypeptide or an HCV E2 polypeptide. The present disclosure provides nucleic acids encoding a polyprotein that includes E1 and variant E2, E2 and variant E1, or variant E2 and variant E1. The present disclosure provides a method of producing an E1/E2 heterodimer of the present disclosure. The present disclosure provides a method of inducing an immune response in an individual. The present disclosure provides variant E2 polypeptides and variant E1 polypeptides; and nucleic acids encoding same.

Implantable medical devices for connecting tissue layers, such as for connecting a gallbladder and a portion of a gastrointestinal tract to create an anastomosis, include a tubular structure having a plurality of apposition portions, a central region, and a covering material. The methods of using the devices include endoscopic deployment, and the devices may include self-expanding frameworks that facilitate a secure connection between the tissue structures.

Anastomosis devices

The present disclosure provides methods and compositions that find use in identifying presence of an advanced stage autoimmune liver disease (ALD) is a subject diagnosed as having ALD. Also provided here are methods and compositions that find use in monitoring effectiveness of treatment of an ALD patient receiving a treatment for the ALD. Also provided here are methods and compositions that find use in identifying subjects suffering from a relapse of ALD. The methods and compositions of the present disclosure also find use in facilitating treatment decisions for a subject having ALD.

Biomarkers in autoimmune liver disease

Provided herein are recombinant cardiomyocytes and cardiomyocyte cell lines expressing human Ether-a-go-go Related Gene (hERG) potassium ion channel, including, for example, stable cell lines, that comprise a transfected or transduced nucleic acid sequence encoding hERG. Also provided herein are methods of using the recombinant cardiomyocytes and cardiomyocyte cell lines expressing hERG for screening compounds for cardiotoxicity, including methods for determining the activity of compounds to inhibit hERG.

Recombinant cardiomyocytes and cardiomyocyte cell lines expressing hERG

Hepatitis c virus immunogenic compositions and methods of use thereof

Hepatitis C virus E1/E2 heterodimers and methods of producing same

Growing community of inventors

Danville, CA, United States of America

Michael Houghton